latest news releases from the newsroom
Skanditek Industriforvaltning AB
Skanditeks Subsidiary CMA Microdialysis AB Announces FDA Clearance
STOCKHOLM, Sweden, Oct. 29, 2002 (PRIMEZONE) -- CMA Microdialysis AB today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the CMA Cerebral Tissue Monitoring System. The system measures intra cranial glucose, lactate, and pyruvate levels as an adjunct monitor to indicate the perfusion status of brain tissue. This is a milestone in the history of the company as it opens one of the largest markets in the world.
Akzo Nobel Acquires German Metalorganics Start-up Company
ARNHEM, The Netherlands, Oct. 29, 2002 (PRIMEZONE) -- Akzo Nobel's (Nasdaq:AKZOY) Polymer Chemicals High Purity Metalorganics (HPMO) unit has strengthened its position in the compound semiconductor industry with the acquisition of Mochem GmbH. The HPMO unit is active in the field of metalorganics for semiconductors in opto-electronics. Mochem is a technology-driven start-up company in the same field with complementary products and know-how.
Tokyo Motor Show: Starting Point for Scania in Japan
SODERTALJE, Sweden, Oct. 29, 2002 (PRIMEZONE) -- Scania (NYSE:SCVa) (NYSE:SCVb) now makes its first appearance at the Tokyo Motor Show, which opens for the public on October 30. The exhibition is the first concrete manifestation of the business alliance between the two leading truck manufacturers Scania and Hino. Scania expects sales to expand slowly but steadily over several years.
BOWE SYSTEC AG
BOEWE SYSTEC AG: 9-Month Report 2002; General Economic Situation Slowing Sales -- 7% on Previous Year; EBITDA Proportional to Sales -- 6.5% on Previous Year
AUGSBURG, Germany, Oct. 29, 2002 (PRIMEZONE) -- This is the first time in eight years that a nine-month report put out by BOEWE SYSTEC (Other OTC:BOEWF) (WKN 523 970) has shown a decline in sales and earnings compared to the previous business year. Against the backdrop of continuing global restraint with regard to investments the European market leader showed sales in high-performance enveloping systems for the first three quarters of business year 2002 amounting to EUR 137.7 million as opposed to EUR 148.2 million last year. There was a decline in operative earnings before interest and depreciation (EBITDA) parallel to the decline shown in sales, amounting to EUR 17.3 million as compared to EUR 18.5 million last year. Earnings on ordinary activities for the same period amounted to EUR 9.4 million as compared to EUR 11.1 million in the first nine months of business year 2001.
Actelion Ltd.: Successful Prevention Study with Tracleer in Scleroderma-Related Digital Ulcerations -- Presented at the American College of Rheumatology
ALLSCHWIL, Switzerland, Oct. 29, 2002 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) announced that Joseph H. Korn, MD, Professor of Medicine and Biochemistry, School of Medicine, Boston University, will present the full results of a successful study with Tracleer(TM) in scleroderma patients suffering from digital ulcerations at today's late-breaking session of the American College of Rheumatology meeting in New Orleans. In this placebo-controlled, multicenter trial, Tracleer(TM) was shown to significantly reduce the occurrence of new digital ulcers (p=0.008).
Salomon Smith Barney and Jack B. Grubman Charged with Securities Fraud by the Pomerantz Firm on Behalf of Purchasers of Level 3 Communications -- LVLT
NEW YORK, Oct. 28, 2002 (PRIMEZONE) -- Pomerantz Haudek Block Grossman & Gross LLP (www.pomerantzlaw.com) has filed a class action lawsuit in the United States District Court for the Southern District of New York against Salomon Smith Barney, Inc. ("Salomon") and its former telecommunications research analyst Jack B. Grubman ("Grubman") on behalf of investors who purchased securities, including the 6% Convertible Subordinated Notes due 2009 (the "Notes"), of Level 3 Communications, Inc. (Nasdaq:LVLT) ("Level 3" or the "Company") during the period from January 4, 1999 through June 18, 2001, inclusive (the "Class Period"). The lawsuit charges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by issuing false and misleading analyst reports on Level 3 in a bid to win or maintain lucrative banking and advisory work from the Company.